Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

OBJECTIVE To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is inadequate in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS Glycemic control, hypoglycemia, and body weight were monitored over 6 years in 826 patients with newly diagnosed type 2 diabetes in 8 of 23 U.K. Prospective Diabetes Study (UKPDS) centers that used a modified protocol. Patients were randomly allocated to a conventional glucose control policy, primarily with diet (n = 242) or an intensive policy with insulin alone (n = 245), as in the main study. However, for patients randomized to an intensive policy with sulfonylurea (n = 339), insulin was added automatically if the fasting plasma glucose remained >108 mg/dl (6.0 mmol/l) despite maximal sulfonylurea doses. RESULTS Over 6 years, approximately 53% of patients allocated to treatment with sulfonylurea required additional insulin therapy. Median HbA(1c) in the sulfonylurea +/- insulin group was significantly lower (6.6%, interquartile range [IQR] 6.0-7.6) than in the group taking insulin alone (7.1%, IQR 6.2-8.0; P = 0.0066), and significantly more patients in the sulfonylurea +/- insulin group had an HbA(1c) <7% (47 vs. 35%, respectively; P = 0.011). Weight gain was similar in the intensive therapy groups, but major hypoglycemia occurred less frequently over all in the sulfonylurea (+/- insulin) group compared with the insulin alone group (1.6 vs. 3.2% per annum, respectively; P = 0.017). CONCLUSIONS Early addition of insulin when maximal sulfonylurea therapy is inadequate can significantly improve glycemic control without promoting increased hypoglycemia or weight gain.

[1]  R. Holman,et al.  Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement , 1987, Diabetic medicine : a journal of the British Diabetic Association.

[2]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[3]  R. Holman,et al.  United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus , 1996, Annals of Internal Medicine.

[4]  R. Holman,et al.  UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal Subjects , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[5]  R. DeFronzo,et al.  Bedtime Insulin/Daytime Glipizide: Effective Therapy for Sulfonylurea Failures in NIDDM , 1995, Diabetes.

[6]  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. , 1991, Diabetologia.

[7]  R. Holman,et al.  A Practical Guide to Basal and Prandial Insulin Therapy , 1985, Diabetic medicine : a journal of the British Diabetic Association.

[8]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[9]  U. Kabadi,et al.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.

[10]  M. Riddle,et al.  Beginning Insulin Treatment of Obese Patients With Evening 70/30 Insulin Plus Glimepiride Versus Insulin Alone , 1998, Diabetes Care.

[11]  Irene M. Stratton,et al.  UK prospective diabetes study (UKPDS) , 2004, Diabetologia.

[12]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .